Craig-Hallum lowered the firm’s price target on Cardlytics to $10 from $12 and keeps a Hold rating on the shares. The company has announced strong Q4 preliminary results in conjunction with settling the SRS dispute over earnouts related to the Bridg acquisition, and its expected Q4 results reflect a record $10M EBITDA, which should begin to reflect the profit-generating capabilities in the business, the analyst tells investors in a research note. The firm adds however that while it is “warming to the Cardlytics story”, the main overhang on the stock – the balance sheet – needs to be resolved.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CDLX:
- Cardlytics Announces Successful Resolution of SRS Dispute and Preliminary Fourth Quarter 2023 Results
- Cardlytics sees Q4 revenue $89M-$90M, consensus $84.7M
- Cardlytics announces resolution of SRS dispute
- Cardlytics files $100M mixed securities shelf
- Cardlytics Appoints Two New Members to its Board of Directors